nodes	percent_of_prediction	percent_of_DWPC	metapath
Lansoprazole—CYP3A4—bone cancer	0.303	1	CbGaD
Lansoprazole—CYP4A11—Cisplatin—bone cancer	0.204	0.439	CbGbCtD
Lansoprazole—CYP1B1—Doxorubicin—bone cancer	0.0569	0.122	CbGbCtD
Lansoprazole—ABCG2—Carboplatin—bone cancer	0.0472	0.101	CbGbCtD
Lansoprazole—ABCG2—Cisplatin—bone cancer	0.0404	0.0866	CbGbCtD
Lansoprazole—ABCG2—Doxorubicin—bone cancer	0.027	0.058	CbGbCtD
Lansoprazole—ABCG2—Methotrexate—bone cancer	0.0262	0.0562	CbGbCtD
Lansoprazole—CYP2C9—Cisplatin—bone cancer	0.015	0.0322	CbGbCtD
Lansoprazole—ABCB1—Cisplatin—bone cancer	0.0145	0.0312	CbGbCtD
Lansoprazole—ABCB1—Doxorubicin—bone cancer	0.00975	0.0209	CbGbCtD
Lansoprazole—ABCB1—Methotrexate—bone cancer	0.00945	0.0203	CbGbCtD
Lansoprazole—CYP2D6—Doxorubicin—bone cancer	0.00919	0.0197	CbGbCtD
Lansoprazole—CYP3A4—Doxorubicin—bone cancer	0.00584	0.0125	CbGbCtD
Lansoprazole—Esomeprazole—CYP3A4—bone cancer	0.00114	0.329	CrCbGaD
Lansoprazole—Pantoprazole—CYP3A4—bone cancer	0.000825	0.238	CrCbGaD
Lansoprazole—Rabeprazole—CYP3A4—bone cancer	0.000825	0.238	CrCbGaD
Lansoprazole—Omeprazole—CYP3A4—bone cancer	0.000672	0.194	CrCbGaD
Lansoprazole—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000308	0.0039	CbGpPWpGaD
Lansoprazole—MAPT—LPA receptor mediated events—JUN—bone cancer	0.000304	0.00386	CbGpPWpGaD
Lansoprazole—MAPT—MAPK Signaling Pathway—TGFBR2—bone cancer	0.000301	0.00381	CbGpPWpGaD
Lansoprazole—CYP1B1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000299	0.00379	CbGpPWpGaD
Lansoprazole—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000298	0.00377	CbGpPWpGaD
Lansoprazole—MAPT—LPA receptor mediated events—MMP9—bone cancer	0.000296	0.00375	CbGpPWpGaD
Lansoprazole—CYP1B1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000295	0.00374	CbGpPWpGaD
Lansoprazole—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000295	0.00374	CbGpPWpGaD
Lansoprazole—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000295	0.00374	CbGpPWpGaD
Lansoprazole—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000283	0.00359	CbGpPWpGaD
Lansoprazole—MAPT—LKB1 signaling events—TP53—bone cancer	0.000276	0.0035	CbGpPWpGaD
Lansoprazole—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000272	0.00345	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000265	0.00336	CbGpPWpGaD
Lansoprazole—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000252	0.0032	CbGpPWpGaD
Lansoprazole—CYP1A1—Estrogen Receptor Pathway—JUN—bone cancer	0.00025	0.00317	CbGpPWpGaD
Lansoprazole—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000249	0.00316	CbGpPWpGaD
Lansoprazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000244	0.0031	CbGpPWpGaD
Lansoprazole—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000243	0.00308	CbGpPWpGaD
Lansoprazole—CYP1B1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000242	0.00307	CbGpPWpGaD
Lansoprazole—MAPT—LPA receptor mediated events—EGFR—bone cancer	0.000239	0.00303	CbGpPWpGaD
Lansoprazole—CYP4A11—Arachidonic acid metabolism—PTGS2—bone cancer	0.000238	0.00302	CbGpPWpGaD
Lansoprazole—MAPT—Copper homeostasis—TP53—bone cancer	0.000237	0.00301	CbGpPWpGaD
Lansoprazole—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000232	0.00294	CbGpPWpGaD
Lansoprazole—CYP2C18—Tryptophan metabolism—MDM2—bone cancer	0.000231	0.00292	CbGpPWpGaD
Lansoprazole—CYP1A1—Tryptophan metabolism—CYP3A4—bone cancer	0.000228	0.00289	CbGpPWpGaD
Lansoprazole—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000227	0.00288	CbGpPWpGaD
Lansoprazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000216	0.00274	CbGpPWpGaD
Lansoprazole—CYP2C18—FOXA1 transcription factor network—JUN—bone cancer	0.000208	0.00263	CbGpPWpGaD
Lansoprazole—CYP4A11—Biological oxidations—CYP3A4—bone cancer	0.0002	0.00253	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000199	0.00253	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.000197	0.0025	CbGpPWpGaD
Lansoprazole—CYP4A11—NRF2 pathway—GSTP1—bone cancer	0.000195	0.00247	CbGpPWpGaD
Lansoprazole—CYP4A11—NRF2 pathway—TGFBR2—bone cancer	0.000195	0.00247	CbGpPWpGaD
Lansoprazole—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000195	0.00247	CbGpPWpGaD
Lansoprazole—MAPT—MAPK Signaling Pathway—BRAF—bone cancer	0.000193	0.00245	CbGpPWpGaD
Lansoprazole—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000187	0.00237	CbGpPWpGaD
Lansoprazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000185	0.00235	CbGpPWpGaD
Lansoprazole—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000184	0.00234	CbGpPWpGaD
Lansoprazole—CYP1A1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000182	0.0023	CbGpPWpGaD
Lansoprazole—CYP2C18—Biological oxidations—CYP3A4—bone cancer	0.000175	0.00221	CbGpPWpGaD
Lansoprazole—CYP2C18—Metapathway biotransformation—CYP3A4—bone cancer	0.000172	0.00218	CbGpPWpGaD
Lansoprazole—CYP4A11—Biological oxidations—GSTP1—bone cancer	0.000171	0.00217	CbGpPWpGaD
Lansoprazole—CYP1B1—Tryptophan metabolism—MDM2—bone cancer	0.00017	0.00216	CbGpPWpGaD
Lansoprazole—MAPT—Alzheimers Disease—TP53—bone cancer	0.00017	0.00215	CbGpPWpGaD
Lansoprazole—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000169	0.00214	CbGpPWpGaD
Lansoprazole—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000167	0.00211	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000164	0.00208	CbGpPWpGaD
Lansoprazole—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.000159	0.00202	CbGpPWpGaD
Lansoprazole—MAPT—BDNF signaling pathway—JUN—bone cancer	0.000159	0.00202	CbGpPWpGaD
Lansoprazole—CYP1B1—Arachidonic acid metabolism—PTGS2—bone cancer	0.000153	0.00194	CbGpPWpGaD
Lansoprazole—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000151	0.00191	CbGpPWpGaD
Lansoprazole—CYP2C18—Biological oxidations—GSTP1—bone cancer	0.000149	0.00189	CbGpPWpGaD
Lansoprazole—CYP1A1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000149	0.00189	CbGpPWpGaD
Lansoprazole—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000149	0.00189	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000148	0.00187	CbGpPWpGaD
Lansoprazole—CYP2C18—Metapathway biotransformation—GSTP1—bone cancer	0.000147	0.00187	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.000146	0.00185	CbGpPWpGaD
Lansoprazole—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000145	0.00184	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.000141	0.00178	CbGpPWpGaD
Lansoprazole—MAPT—MAPK Signaling Pathway—JUN—bone cancer	0.00014	0.00178	CbGpPWpGaD
Lansoprazole—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000139	0.00176	CbGpPWpGaD
Lansoprazole—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000137	0.00174	CbGpPWpGaD
Lansoprazole—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000137	0.00174	CbGpPWpGaD
Lansoprazole—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000137	0.00173	CbGpPWpGaD
Lansoprazole—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000136	0.00172	CbGpPWpGaD
Lansoprazole—CYP1B1—Biological oxidations—CYP3A4—bone cancer	0.000129	0.00163	CbGpPWpGaD
Lansoprazole—CYP1B1—Metapathway biotransformation—CYP3A4—bone cancer	0.000127	0.00161	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	0.000127	0.00161	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000123	0.00156	CbGpPWpGaD
Lansoprazole—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000122	0.00155	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—NDUFA12—bone cancer	0.00012	0.00152	CbGpPWpGaD
Lansoprazole—Neuropathy peripheral—Doxorubicin—bone cancer	0.000118	0.000794	CcSEcCtD
Lansoprazole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000117	0.00149	CbGpPWpGaD
Lansoprazole—Jaundice—Doxorubicin—bone cancer	0.000117	0.000789	CcSEcCtD
Lansoprazole—Stomatitis—Doxorubicin—bone cancer	0.000117	0.000789	CcSEcCtD
Lansoprazole—Rhinitis—Epirubicin—bone cancer	0.000117	0.000788	CcSEcCtD
Lansoprazole—Conjunctivitis—Doxorubicin—bone cancer	0.000117	0.000787	CcSEcCtD
Lansoprazole—Urinary tract infection—Doxorubicin—bone cancer	0.000117	0.000787	CcSEcCtD
Lansoprazole—Hepatitis—Epirubicin—bone cancer	0.000117	0.000786	CcSEcCtD
Lansoprazole—Eye disorder—Methotrexate—bone cancer	0.000116	0.000785	CcSEcCtD
Lansoprazole—Tinnitus—Methotrexate—bone cancer	0.000116	0.000783	CcSEcCtD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000116	0.00147	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.000116	0.00147	CbGpPWpGaD
Lansoprazole—Hypoaesthesia—Epirubicin—bone cancer	0.000116	0.000782	CcSEcCtD
Lansoprazole—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000116	0.00147	CbGpPWpGaD
Lansoprazole—Asthenia—Cisplatin—bone cancer	0.000116	0.00078	CcSEcCtD
Lansoprazole—Pharyngitis—Epirubicin—bone cancer	0.000116	0.00078	CcSEcCtD
Lansoprazole—ABCG2—Fluoropyrimidine Activity—TP53—bone cancer	0.000116	0.00147	CbGpPWpGaD
Lansoprazole—Cardiac disorder—Methotrexate—bone cancer	0.000116	0.000779	CcSEcCtD
Lansoprazole—Sweating—Doxorubicin—bone cancer	0.000115	0.000776	CcSEcCtD
Lansoprazole—Urinary tract disorder—Epirubicin—bone cancer	0.000115	0.000776	CcSEcCtD
Lansoprazole—Oedema peripheral—Epirubicin—bone cancer	0.000115	0.000774	CcSEcCtD
Lansoprazole—Haematuria—Doxorubicin—bone cancer	0.000115	0.000772	CcSEcCtD
Lansoprazole—Connective tissue disorder—Epirubicin—bone cancer	0.000115	0.000772	CcSEcCtD
Lansoprazole—Urethral disorder—Epirubicin—bone cancer	0.000114	0.00077	CcSEcCtD
Lansoprazole—Hepatobiliary disease—Doxorubicin—bone cancer	0.000114	0.000766	CcSEcCtD
Lansoprazole—Epistaxis—Doxorubicin—bone cancer	0.000113	0.000764	CcSEcCtD
Lansoprazole—Angiopathy—Methotrexate—bone cancer	0.000113	0.000762	CcSEcCtD
Lansoprazole—Sinusitis—Doxorubicin—bone cancer	0.000113	0.00076	CcSEcCtD
Lansoprazole—Immune system disorder—Methotrexate—bone cancer	0.000113	0.000758	CcSEcCtD
Lansoprazole—Visual impairment—Epirubicin—bone cancer	0.000112	0.000757	CcSEcCtD
Lansoprazole—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000112	0.00142	CbGpPWpGaD
Lansoprazole—Mediastinal disorder—Methotrexate—bone cancer	0.000112	0.000757	CcSEcCtD
Lansoprazole—Agranulocytosis—Doxorubicin—bone cancer	0.000112	0.000756	CcSEcCtD
Lansoprazole—Chills—Methotrexate—bone cancer	0.000112	0.000753	CcSEcCtD
Lansoprazole—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000111	0.00141	CbGpPWpGaD
Lansoprazole—MAPT—MAPK Signaling Pathway—EGFR—bone cancer	0.00011	0.0014	CbGpPWpGaD
Lansoprazole—Diarrhoea—Cisplatin—bone cancer	0.00011	0.000744	CcSEcCtD
Lansoprazole—Erythema multiforme—Epirubicin—bone cancer	0.00011	0.000743	CcSEcCtD
Lansoprazole—Alopecia—Methotrexate—bone cancer	0.00011	0.000742	CcSEcCtD
Lansoprazole—CYP1B1—Biological oxidations—GSTP1—bone cancer	0.00011	0.0014	CbGpPWpGaD
Lansoprazole—Bradycardia—Doxorubicin—bone cancer	0.00011	0.00074	CcSEcCtD
Lansoprazole—Mental disorder—Methotrexate—bone cancer	0.000109	0.000736	CcSEcCtD
Lansoprazole—Eye disorder—Epirubicin—bone cancer	0.000109	0.000734	CcSEcCtD
Lansoprazole—Tinnitus—Epirubicin—bone cancer	0.000109	0.000733	CcSEcCtD
Lansoprazole—CYP1B1—Metapathway biotransformation—GSTP1—bone cancer	0.000109	0.00138	CbGpPWpGaD
Lansoprazole—Erythema—Methotrexate—bone cancer	0.000108	0.000731	CcSEcCtD
Lansoprazole—Malnutrition—Methotrexate—bone cancer	0.000108	0.000731	CcSEcCtD
Lansoprazole—Cardiac disorder—Epirubicin—bone cancer	0.000108	0.000729	CcSEcCtD
Lansoprazole—Rhinitis—Doxorubicin—bone cancer	0.000108	0.000729	CcSEcCtD
Lansoprazole—Hepatitis—Doxorubicin—bone cancer	0.000108	0.000727	CcSEcCtD
Lansoprazole—Hypoaesthesia—Doxorubicin—bone cancer	0.000107	0.000723	CcSEcCtD
Lansoprazole—Pharyngitis—Doxorubicin—bone cancer	0.000107	0.000722	CcSEcCtD
Lansoprazole—Urinary tract disorder—Doxorubicin—bone cancer	0.000107	0.000718	CcSEcCtD
Lansoprazole—Oedema peripheral—Doxorubicin—bone cancer	0.000106	0.000716	CcSEcCtD
Lansoprazole—Dysgeusia—Methotrexate—bone cancer	0.000106	0.000716	CcSEcCtD
Lansoprazole—Connective tissue disorder—Doxorubicin—bone cancer	0.000106	0.000714	CcSEcCtD
Lansoprazole—Angiopathy—Epirubicin—bone cancer	0.000106	0.000713	CcSEcCtD
Lansoprazole—Urethral disorder—Doxorubicin—bone cancer	0.000106	0.000713	CcSEcCtD
Lansoprazole—Immune system disorder—Epirubicin—bone cancer	0.000105	0.00071	CcSEcCtD
Lansoprazole—Mediastinal disorder—Epirubicin—bone cancer	0.000105	0.000708	CcSEcCtD
Lansoprazole—Back pain—Methotrexate—bone cancer	0.000105	0.000707	CcSEcCtD
Lansoprazole—CYP2C18—Metabolism—NDUFA12—bone cancer	0.000105	0.00133	CbGpPWpGaD
Lansoprazole—CYP1A1—Tryptophan metabolism—MDM2—bone cancer	0.000105	0.00133	CbGpPWpGaD
Lansoprazole—Chills—Epirubicin—bone cancer	0.000105	0.000705	CcSEcCtD
Lansoprazole—Arrhythmia—Epirubicin—bone cancer	0.000104	0.000702	CcSEcCtD
Lansoprazole—Visual impairment—Doxorubicin—bone cancer	0.000104	0.000701	CcSEcCtD
Lansoprazole—Alopecia—Epirubicin—bone cancer	0.000103	0.000694	CcSEcCtD
Lansoprazole—Vomiting—Cisplatin—bone cancer	0.000103	0.000691	CcSEcCtD
Lansoprazole—Vision blurred—Methotrexate—bone cancer	0.000102	0.000689	CcSEcCtD
Lansoprazole—Mental disorder—Epirubicin—bone cancer	0.000102	0.000688	CcSEcCtD
Lansoprazole—Erythema multiforme—Doxorubicin—bone cancer	0.000102	0.000687	CcSEcCtD
Lansoprazole—Rash—Cisplatin—bone cancer	0.000102	0.000685	CcSEcCtD
Lansoprazole—Dermatitis—Cisplatin—bone cancer	0.000102	0.000685	CcSEcCtD
Lansoprazole—Malnutrition—Epirubicin—bone cancer	0.000102	0.000684	CcSEcCtD
Lansoprazole—Erythema—Epirubicin—bone cancer	0.000102	0.000684	CcSEcCtD
Lansoprazole—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000101	0.00128	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000101	0.00128	CbGpPWpGaD
Lansoprazole—Eye disorder—Doxorubicin—bone cancer	0.000101	0.000679	CcSEcCtD
Lansoprazole—ABCG2—HIF-1-alpha transcription factor network—JUN—bone cancer	0.000101	0.00128	CbGpPWpGaD
Lansoprazole—Ill-defined disorder—Methotrexate—bone cancer	0.000101	0.000678	CcSEcCtD
Lansoprazole—Tinnitus—Doxorubicin—bone cancer	0.000101	0.000678	CcSEcCtD
Lansoprazole—Anaemia—Methotrexate—bone cancer	0.0001	0.000676	CcSEcCtD
Lansoprazole—Cardiac disorder—Doxorubicin—bone cancer	0.0001	0.000675	CcSEcCtD
Lansoprazole—Flatulence—Epirubicin—bone cancer	0.0001	0.000674	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	9.97e-05	0.00126	CbGpPWpGaD
Lansoprazole—Tension—Epirubicin—bone cancer	9.96e-05	0.000671	CcSEcCtD
Lansoprazole—Dysgeusia—Epirubicin—bone cancer	9.94e-05	0.00067	CcSEcCtD
Lansoprazole—CYP4A11—Metabolism—NT5C3A—bone cancer	9.92e-05	0.00126	CbGpPWpGaD
Lansoprazole—MAPT—Apoptosis—TP53—bone cancer	9.89e-05	0.00125	CbGpPWpGaD
Lansoprazole—Nervousness—Epirubicin—bone cancer	9.86e-05	0.000664	CcSEcCtD
Lansoprazole—Back pain—Epirubicin—bone cancer	9.82e-05	0.000662	CcSEcCtD
Lansoprazole—Angiopathy—Doxorubicin—bone cancer	9.79e-05	0.00066	CcSEcCtD
Lansoprazole—Malaise—Methotrexate—bone cancer	9.78e-05	0.000659	CcSEcCtD
Lansoprazole—Muscle spasms—Epirubicin—bone cancer	9.76e-05	0.000658	CcSEcCtD
Lansoprazole—Immune system disorder—Doxorubicin—bone cancer	9.75e-05	0.000657	CcSEcCtD
Lansoprazole—Vertigo—Methotrexate—bone cancer	9.75e-05	0.000657	CcSEcCtD
Lansoprazole—Mediastinal disorder—Doxorubicin—bone cancer	9.73e-05	0.000655	CcSEcCtD
Lansoprazole—Leukopenia—Methotrexate—bone cancer	9.71e-05	0.000654	CcSEcCtD
Lansoprazole—Chills—Doxorubicin—bone cancer	9.68e-05	0.000652	CcSEcCtD
Lansoprazole—Arrhythmia—Doxorubicin—bone cancer	9.64e-05	0.000649	CcSEcCtD
Lansoprazole—Nausea—Cisplatin—bone cancer	9.59e-05	0.000646	CcSEcCtD
Lansoprazole—Vision blurred—Epirubicin—bone cancer	9.57e-05	0.000645	CcSEcCtD
Lansoprazole—Alopecia—Doxorubicin—bone cancer	9.54e-05	0.000642	CcSEcCtD
Lansoprazole—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	9.52e-05	0.00121	CbGpPWpGaD
Lansoprazole—Cough—Methotrexate—bone cancer	9.47e-05	0.000638	CcSEcCtD
Lansoprazole—Mental disorder—Doxorubicin—bone cancer	9.46e-05	0.000637	CcSEcCtD
Lansoprazole—CYP1A1—Arachidonic acid metabolism—PTGS2—bone cancer	9.44e-05	0.0012	CbGpPWpGaD
Lansoprazole—Ill-defined disorder—Epirubicin—bone cancer	9.42e-05	0.000635	CcSEcCtD
Lansoprazole—Convulsion—Methotrexate—bone cancer	9.4e-05	0.000633	CcSEcCtD
Lansoprazole—Malnutrition—Doxorubicin—bone cancer	9.39e-05	0.000633	CcSEcCtD
Lansoprazole—Erythema—Doxorubicin—bone cancer	9.39e-05	0.000633	CcSEcCtD
Lansoprazole—Anaemia—Epirubicin—bone cancer	9.38e-05	0.000632	CcSEcCtD
Lansoprazole—Agitation—Epirubicin—bone cancer	9.33e-05	0.000629	CcSEcCtD
Lansoprazole—MAPT—MAPK Signaling Pathway—TP53—bone cancer	9.27e-05	0.00118	CbGpPWpGaD
Lansoprazole—Flatulence—Doxorubicin—bone cancer	9.26e-05	0.000624	CcSEcCtD
Lansoprazole—Myalgia—Methotrexate—bone cancer	9.24e-05	0.000622	CcSEcCtD
Lansoprazole—Chest pain—Methotrexate—bone cancer	9.24e-05	0.000622	CcSEcCtD
Lansoprazole—Arthralgia—Methotrexate—bone cancer	9.24e-05	0.000622	CcSEcCtD
Lansoprazole—Tension—Doxorubicin—bone cancer	9.22e-05	0.000621	CcSEcCtD
Lansoprazole—Dysgeusia—Doxorubicin—bone cancer	9.2e-05	0.00062	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	9.17e-05	0.000618	CcSEcCtD
Lansoprazole—Malaise—Epirubicin—bone cancer	9.16e-05	0.000617	CcSEcCtD
Lansoprazole—Discomfort—Methotrexate—bone cancer	9.13e-05	0.000615	CcSEcCtD
Lansoprazole—Nervousness—Doxorubicin—bone cancer	9.12e-05	0.000615	CcSEcCtD
Lansoprazole—Vertigo—Epirubicin—bone cancer	9.12e-05	0.000615	CcSEcCtD
Lansoprazole—Syncope—Epirubicin—bone cancer	9.11e-05	0.000613	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	9.1e-05	0.00115	CbGpPWpGaD
Lansoprazole—Leukopenia—Epirubicin—bone cancer	9.09e-05	0.000612	CcSEcCtD
Lansoprazole—Back pain—Doxorubicin—bone cancer	9.09e-05	0.000612	CcSEcCtD
Lansoprazole—Muscle spasms—Doxorubicin—bone cancer	9.03e-05	0.000608	CcSEcCtD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—TUBB4B—bone cancer	8.98e-05	0.00114	CbGpPWpGaD
Lansoprazole—Palpitations—Epirubicin—bone cancer	8.97e-05	0.000604	CcSEcCtD
Lansoprazole—Confusional state—Methotrexate—bone cancer	8.93e-05	0.000601	CcSEcCtD
Lansoprazole—Loss of consciousness—Epirubicin—bone cancer	8.92e-05	0.000601	CcSEcCtD
Lansoprazole—Cough—Epirubicin—bone cancer	8.86e-05	0.000597	CcSEcCtD
Lansoprazole—Anaphylactic shock—Methotrexate—bone cancer	8.86e-05	0.000597	CcSEcCtD
Lansoprazole—Vision blurred—Doxorubicin—bone cancer	8.85e-05	0.000596	CcSEcCtD
Lansoprazole—Convulsion—Epirubicin—bone cancer	8.8e-05	0.000593	CcSEcCtD
Lansoprazole—Infection—Methotrexate—bone cancer	8.8e-05	0.000593	CcSEcCtD
Lansoprazole—Hypertension—Epirubicin—bone cancer	8.77e-05	0.000591	CcSEcCtD
Lansoprazole—Ill-defined disorder—Doxorubicin—bone cancer	8.72e-05	0.000587	CcSEcCtD
Lansoprazole—Nervous system disorder—Methotrexate—bone cancer	8.68e-05	0.000585	CcSEcCtD
Lansoprazole—Anaemia—Doxorubicin—bone cancer	8.68e-05	0.000585	CcSEcCtD
Lansoprazole—CYP2C18—Metabolism—NT5C3A—bone cancer	8.67e-05	0.0011	CbGpPWpGaD
Lansoprazole—Thrombocytopenia—Methotrexate—bone cancer	8.67e-05	0.000584	CcSEcCtD
Lansoprazole—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	8.65e-05	0.0011	CbGpPWpGaD
Lansoprazole—Chest pain—Epirubicin—bone cancer	8.64e-05	0.000582	CcSEcCtD
Lansoprazole—Arthralgia—Epirubicin—bone cancer	8.64e-05	0.000582	CcSEcCtD
Lansoprazole—Myalgia—Epirubicin—bone cancer	8.64e-05	0.000582	CcSEcCtD
Lansoprazole—Agitation—Doxorubicin—bone cancer	8.63e-05	0.000582	CcSEcCtD
Lansoprazole—Anxiety—Epirubicin—bone cancer	8.61e-05	0.00058	CcSEcCtD
Lansoprazole—Skin disorder—Methotrexate—bone cancer	8.6e-05	0.000579	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	8.58e-05	0.000578	CcSEcCtD
Lansoprazole—Hyperhidrosis—Methotrexate—bone cancer	8.56e-05	0.000577	CcSEcCtD
Lansoprazole—Discomfort—Epirubicin—bone cancer	8.54e-05	0.000575	CcSEcCtD
Lansoprazole—Malaise—Doxorubicin—bone cancer	8.47e-05	0.000571	CcSEcCtD
Lansoprazole—Dry mouth—Epirubicin—bone cancer	8.45e-05	0.00057	CcSEcCtD
Lansoprazole—Vertigo—Doxorubicin—bone cancer	8.44e-05	0.000569	CcSEcCtD
Lansoprazole—Anorexia—Methotrexate—bone cancer	8.44e-05	0.000569	CcSEcCtD
Lansoprazole—Syncope—Doxorubicin—bone cancer	8.43e-05	0.000568	CcSEcCtD
Lansoprazole—Leukopenia—Doxorubicin—bone cancer	8.41e-05	0.000567	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	8.37e-05	0.00106	CbGpPWpGaD
Lansoprazole—Confusional state—Epirubicin—bone cancer	8.36e-05	0.000563	CcSEcCtD
Lansoprazole—Palpitations—Doxorubicin—bone cancer	8.3e-05	0.000559	CcSEcCtD
Lansoprazole—Anaphylactic shock—Epirubicin—bone cancer	8.29e-05	0.000558	CcSEcCtD
Lansoprazole—Oedema—Epirubicin—bone cancer	8.29e-05	0.000558	CcSEcCtD
Lansoprazole—Hypotension—Methotrexate—bone cancer	8.27e-05	0.000557	CcSEcCtD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	8.26e-05	0.00105	CbGpPWpGaD
Lansoprazole—Loss of consciousness—Doxorubicin—bone cancer	8.26e-05	0.000556	CcSEcCtD
Lansoprazole—Infection—Epirubicin—bone cancer	8.23e-05	0.000555	CcSEcCtD
Lansoprazole—Cough—Doxorubicin—bone cancer	8.2e-05	0.000552	CcSEcCtD
Lansoprazole—Shock—Epirubicin—bone cancer	8.15e-05	0.000549	CcSEcCtD
Lansoprazole—Convulsion—Doxorubicin—bone cancer	8.14e-05	0.000548	CcSEcCtD
Lansoprazole—Nervous system disorder—Epirubicin—bone cancer	8.13e-05	0.000547	CcSEcCtD
Lansoprazole—Thrombocytopenia—Epirubicin—bone cancer	8.11e-05	0.000547	CcSEcCtD
Lansoprazole—Hypertension—Doxorubicin—bone cancer	8.11e-05	0.000546	CcSEcCtD
Lansoprazole—Tachycardia—Epirubicin—bone cancer	8.09e-05	0.000545	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Methotrexate—bone cancer	8.07e-05	0.000543	CcSEcCtD
Lansoprazole—Skin disorder—Epirubicin—bone cancer	8.05e-05	0.000542	CcSEcCtD
Lansoprazole—Hyperhidrosis—Epirubicin—bone cancer	8.01e-05	0.00054	CcSEcCtD
Lansoprazole—Insomnia—Methotrexate—bone cancer	8.01e-05	0.00054	CcSEcCtD
Lansoprazole—Chest pain—Doxorubicin—bone cancer	8e-05	0.000539	CcSEcCtD
Lansoprazole—Arthralgia—Doxorubicin—bone cancer	8e-05	0.000539	CcSEcCtD
Lansoprazole—Myalgia—Doxorubicin—bone cancer	8e-05	0.000539	CcSEcCtD
Lansoprazole—Anxiety—Doxorubicin—bone cancer	7.97e-05	0.000537	CcSEcCtD
Lansoprazole—Paraesthesia—Methotrexate—bone cancer	7.95e-05	0.000536	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	7.94e-05	0.000535	CcSEcCtD
Lansoprazole—CYP1A1—Biological oxidations—CYP3A4—bone cancer	7.93e-05	0.00101	CbGpPWpGaD
Lansoprazole—Discomfort—Doxorubicin—bone cancer	7.9e-05	0.000532	CcSEcCtD
Lansoprazole—Anorexia—Epirubicin—bone cancer	7.9e-05	0.000532	CcSEcCtD
Lansoprazole—Dyspnoea—Methotrexate—bone cancer	7.89e-05	0.000532	CcSEcCtD
Lansoprazole—Somnolence—Methotrexate—bone cancer	7.87e-05	0.00053	CcSEcCtD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	7.83e-05	0.000993	CbGpPWpGaD
Lansoprazole—Dry mouth—Doxorubicin—bone cancer	7.82e-05	0.000527	CcSEcCtD
Lansoprazole—CYP1A1—Metapathway biotransformation—CYP3A4—bone cancer	7.82e-05	0.000992	CbGpPWpGaD
Lansoprazole—Dyspepsia—Methotrexate—bone cancer	7.79e-05	0.000525	CcSEcCtD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.75e-05	0.000983	CbGpPWpGaD
Lansoprazole—Hypotension—Epirubicin—bone cancer	7.74e-05	0.000522	CcSEcCtD
Lansoprazole—Confusional state—Doxorubicin—bone cancer	7.73e-05	0.000521	CcSEcCtD
Lansoprazole—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	7.72e-05	0.00098	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—NDUFA12—bone cancer	7.72e-05	0.000979	CbGpPWpGaD
Lansoprazole—Decreased appetite—Methotrexate—bone cancer	7.7e-05	0.000519	CcSEcCtD
Lansoprazole—Oedema—Doxorubicin—bone cancer	7.67e-05	0.000517	CcSEcCtD
Lansoprazole—Anaphylactic shock—Doxorubicin—bone cancer	7.67e-05	0.000517	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Methotrexate—bone cancer	7.64e-05	0.000515	CcSEcCtD
Lansoprazole—Fatigue—Methotrexate—bone cancer	7.63e-05	0.000514	CcSEcCtD
Lansoprazole—Infection—Doxorubicin—bone cancer	7.62e-05	0.000513	CcSEcCtD
Lansoprazole—Pain—Methotrexate—bone cancer	7.57e-05	0.00051	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Epirubicin—bone cancer	7.55e-05	0.000509	CcSEcCtD
Lansoprazole—Shock—Doxorubicin—bone cancer	7.54e-05	0.000508	CcSEcCtD
Lansoprazole—Nervous system disorder—Doxorubicin—bone cancer	7.52e-05	0.000507	CcSEcCtD
Lansoprazole—Thrombocytopenia—Doxorubicin—bone cancer	7.51e-05	0.000506	CcSEcCtD
Lansoprazole—Insomnia—Epirubicin—bone cancer	7.5e-05	0.000505	CcSEcCtD
Lansoprazole—Tachycardia—Doxorubicin—bone cancer	7.48e-05	0.000504	CcSEcCtD
Lansoprazole—Skin disorder—Doxorubicin—bone cancer	7.45e-05	0.000502	CcSEcCtD
Lansoprazole—Paraesthesia—Epirubicin—bone cancer	7.44e-05	0.000501	CcSEcCtD
Lansoprazole—Hyperhidrosis—Doxorubicin—bone cancer	7.41e-05	0.000499	CcSEcCtD
Lansoprazole—CYP1A2—Phase II conjugation—GSTP1—bone cancer	7.39e-05	0.000937	CbGpPWpGaD
Lansoprazole—Dyspnoea—Epirubicin—bone cancer	7.39e-05	0.000498	CcSEcCtD
Lansoprazole—Somnolence—Epirubicin—bone cancer	7.37e-05	0.000496	CcSEcCtD
Lansoprazole—Anorexia—Doxorubicin—bone cancer	7.31e-05	0.000492	CcSEcCtD
Lansoprazole—Feeling abnormal—Methotrexate—bone cancer	7.3e-05	0.000492	CcSEcCtD
Lansoprazole—Dyspepsia—Epirubicin—bone cancer	7.29e-05	0.000491	CcSEcCtD
Lansoprazole—CYP2C8—Biological oxidations—CYP3A4—bone cancer	7.27e-05	0.000922	CbGpPWpGaD
Lansoprazole—Gastrointestinal pain—Methotrexate—bone cancer	7.24e-05	0.000488	CcSEcCtD
Lansoprazole—Decreased appetite—Epirubicin—bone cancer	7.2e-05	0.000485	CcSEcCtD
Lansoprazole—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	7.17e-05	0.000909	CbGpPWpGaD
Lansoprazole—Hypotension—Doxorubicin—bone cancer	7.16e-05	0.000483	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Epirubicin—bone cancer	7.15e-05	0.000482	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—bone cancer	7.15e-05	0.000907	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	7.15e-05	0.000907	CbGpPWpGaD
Lansoprazole—Fatigue—Epirubicin—bone cancer	7.14e-05	0.000481	CcSEcCtD
Lansoprazole—Pain—Epirubicin—bone cancer	7.09e-05	0.000477	CcSEcCtD
Lansoprazole—Constipation—Epirubicin—bone cancer	7.09e-05	0.000477	CcSEcCtD
Lansoprazole—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	7.04e-05	0.000893	CbGpPWpGaD
Lansoprazole—Urticaria—Methotrexate—bone cancer	7.03e-05	0.000474	CcSEcCtD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	7.02e-05	0.000891	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—NDUFA12—bone cancer	7.02e-05	0.00089	CbGpPWpGaD
Lansoprazole—Abdominal pain—Methotrexate—bone cancer	7e-05	0.000472	CcSEcCtD
Lansoprazole—Body temperature increased—Methotrexate—bone cancer	7e-05	0.000472	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Doxorubicin—bone cancer	6.99e-05	0.000471	CcSEcCtD
Lansoprazole—Insomnia—Doxorubicin—bone cancer	6.94e-05	0.000467	CcSEcCtD
Lansoprazole—Paraesthesia—Doxorubicin—bone cancer	6.89e-05	0.000464	CcSEcCtD
Lansoprazole—Dyspnoea—Doxorubicin—bone cancer	6.84e-05	0.00046	CcSEcCtD
Lansoprazole—Feeling abnormal—Epirubicin—bone cancer	6.83e-05	0.00046	CcSEcCtD
Lansoprazole—Somnolence—Doxorubicin—bone cancer	6.82e-05	0.000459	CcSEcCtD
Lansoprazole—CYP1A1—Biological oxidations—GSTP1—bone cancer	6.78e-05	0.00086	CbGpPWpGaD
Lansoprazole—Gastrointestinal pain—Epirubicin—bone cancer	6.78e-05	0.000456	CcSEcCtD
Lansoprazole—Dyspepsia—Doxorubicin—bone cancer	6.75e-05	0.000455	CcSEcCtD
Lansoprazole—CYP1A1—Metapathway biotransformation—GSTP1—bone cancer	6.69e-05	0.000848	CbGpPWpGaD
Lansoprazole—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	6.67e-05	0.000846	CbGpPWpGaD
Lansoprazole—Decreased appetite—Doxorubicin—bone cancer	6.67e-05	0.000449	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Doxorubicin—bone cancer	6.62e-05	0.000446	CcSEcCtD
Lansoprazole—Fatigue—Doxorubicin—bone cancer	6.61e-05	0.000445	CcSEcCtD
Lansoprazole—Urticaria—Epirubicin—bone cancer	6.58e-05	0.000443	CcSEcCtD
Lansoprazole—Constipation—Doxorubicin—bone cancer	6.56e-05	0.000442	CcSEcCtD
Lansoprazole—Pain—Doxorubicin—bone cancer	6.56e-05	0.000442	CcSEcCtD
Lansoprazole—Body temperature increased—Epirubicin—bone cancer	6.55e-05	0.000441	CcSEcCtD
Lansoprazole—Abdominal pain—Epirubicin—bone cancer	6.55e-05	0.000441	CcSEcCtD
Lansoprazole—Hypersensitivity—Methotrexate—bone cancer	6.52e-05	0.000439	CcSEcCtD
Lansoprazole—CYP2C19—Biological oxidations—CYP3A4—bone cancer	6.49e-05	0.000823	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	6.43e-05	0.000816	CbGpPWpGaD
Lansoprazole—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	6.4e-05	0.000812	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	6.39e-05	0.000811	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—NT5C3A—bone cancer	6.39e-05	0.000811	CbGpPWpGaD
Lansoprazole—Asthenia—Methotrexate—bone cancer	6.35e-05	0.000428	CcSEcCtD
Lansoprazole—Feeling abnormal—Doxorubicin—bone cancer	6.32e-05	0.000426	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Doxorubicin—bone cancer	6.27e-05	0.000422	CcSEcCtD
Lansoprazole—Pruritus—Methotrexate—bone cancer	6.26e-05	0.000422	CcSEcCtD
Lansoprazole—CYP2C8—Biological oxidations—GSTP1—bone cancer	6.22e-05	0.000788	CbGpPWpGaD
Lansoprazole—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	6.13e-05	0.000778	CbGpPWpGaD
Lansoprazole—Hypersensitivity—Epirubicin—bone cancer	6.11e-05	0.000411	CcSEcCtD
Lansoprazole—Urticaria—Doxorubicin—bone cancer	6.09e-05	0.00041	CcSEcCtD
Lansoprazole—Abdominal pain—Doxorubicin—bone cancer	6.06e-05	0.000408	CcSEcCtD
Lansoprazole—Body temperature increased—Doxorubicin—bone cancer	6.06e-05	0.000408	CcSEcCtD
Lansoprazole—Diarrhoea—Methotrexate—bone cancer	6.06e-05	0.000408	CcSEcCtD
Lansoprazole—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	6.02e-05	0.000763	CbGpPWpGaD
Lansoprazole—CYP2D6—Biological oxidations—CYP3A4—bone cancer	5.97e-05	0.000757	CbGpPWpGaD
Lansoprazole—Asthenia—Epirubicin—bone cancer	5.95e-05	0.000401	CcSEcCtD
Lansoprazole—CYP2C9—Biological oxidations—CYP3A4—bone cancer	5.92e-05	0.00075	CbGpPWpGaD
Lansoprazole—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	5.89e-05	0.000746	CbGpPWpGaD
Lansoprazole—Pruritus—Epirubicin—bone cancer	5.86e-05	0.000395	CcSEcCtD
Lansoprazole—Dizziness—Methotrexate—bone cancer	5.86e-05	0.000394	CcSEcCtD
Lansoprazole—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	5.83e-05	0.00074	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	5.82e-05	0.000739	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—NT5C3A—bone cancer	5.82e-05	0.000738	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	5.8e-05	0.000736	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	5.74e-05	0.000729	CbGpPWpGaD
Lansoprazole—Diarrhoea—Epirubicin—bone cancer	5.67e-05	0.000382	CcSEcCtD
Lansoprazole—Hypersensitivity—Doxorubicin—bone cancer	5.65e-05	0.000381	CcSEcCtD
Lansoprazole—Vomiting—Methotrexate—bone cancer	5.63e-05	0.000379	CcSEcCtD
Lansoprazole—Rash—Methotrexate—bone cancer	5.58e-05	0.000376	CcSEcCtD
Lansoprazole—Dermatitis—Methotrexate—bone cancer	5.58e-05	0.000376	CcSEcCtD
Lansoprazole—CYP2C19—Biological oxidations—GSTP1—bone cancer	5.55e-05	0.000704	CbGpPWpGaD
Lansoprazole—Headache—Methotrexate—bone cancer	5.55e-05	0.000374	CcSEcCtD
Lansoprazole—Asthenia—Doxorubicin—bone cancer	5.5e-05	0.000371	CcSEcCtD
Lansoprazole—Dizziness—Epirubicin—bone cancer	5.48e-05	0.000369	CcSEcCtD
Lansoprazole—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	5.47e-05	0.000694	CbGpPWpGaD
Lansoprazole—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	5.44e-05	0.00069	CbGpPWpGaD
Lansoprazole—Pruritus—Doxorubicin—bone cancer	5.42e-05	0.000365	CcSEcCtD
Lansoprazole—Vomiting—Epirubicin—bone cancer	5.27e-05	0.000355	CcSEcCtD
Lansoprazole—Nausea—Methotrexate—bone cancer	5.26e-05	0.000354	CcSEcCtD
Lansoprazole—Diarrhoea—Doxorubicin—bone cancer	5.25e-05	0.000353	CcSEcCtD
Lansoprazole—Rash—Epirubicin—bone cancer	5.22e-05	0.000352	CcSEcCtD
Lansoprazole—Dermatitis—Epirubicin—bone cancer	5.22e-05	0.000352	CcSEcCtD
Lansoprazole—Headache—Epirubicin—bone cancer	5.19e-05	0.00035	CcSEcCtD
Lansoprazole—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	5.15e-05	0.000653	CbGpPWpGaD
Lansoprazole—CYP2D6—Biological oxidations—GSTP1—bone cancer	5.1e-05	0.000647	CbGpPWpGaD
Lansoprazole—Dizziness—Doxorubicin—bone cancer	5.07e-05	0.000342	CcSEcCtD
Lansoprazole—CYP2C9—Biological oxidations—GSTP1—bone cancer	5.06e-05	0.000642	CbGpPWpGaD
Lansoprazole—CYP1A2—Biological oxidations—CYP3A4—bone cancer	5.06e-05	0.000641	CbGpPWpGaD
Lansoprazole—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	5.03e-05	0.000638	CbGpPWpGaD
Lansoprazole—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	4.99e-05	0.000633	CbGpPWpGaD
Lansoprazole—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	4.99e-05	0.000632	CbGpPWpGaD
Lansoprazole—Nausea—Epirubicin—bone cancer	4.92e-05	0.000332	CcSEcCtD
Lansoprazole—Vomiting—Doxorubicin—bone cancer	4.88e-05	0.000328	CcSEcCtD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	4.87e-05	0.000617	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	4.85e-05	0.000616	CbGpPWpGaD
Lansoprazole—Rash—Doxorubicin—bone cancer	4.83e-05	0.000326	CcSEcCtD
Lansoprazole—Dermatitis—Doxorubicin—bone cancer	4.83e-05	0.000325	CcSEcCtD
Lansoprazole—Headache—Doxorubicin—bone cancer	4.8e-05	0.000324	CcSEcCtD
Lansoprazole—CYP1A1—Metabolism—NDUFA12—bone cancer	4.75e-05	0.000603	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	4.56e-05	0.000578	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	4.56e-05	0.000578	CbGpPWpGaD
Lansoprazole—Nausea—Doxorubicin—bone cancer	4.55e-05	0.000307	CcSEcCtD
Lansoprazole—CYP2C8—Metabolism—NDUFA12—bone cancer	4.36e-05	0.000553	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—ENO2—bone cancer	4.35e-05	0.000551	CbGpPWpGaD
Lansoprazole—CYP1A2—Biological oxidations—GSTP1—bone cancer	4.32e-05	0.000548	CbGpPWpGaD
Lansoprazole—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	4.26e-05	0.000541	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	4.19e-05	0.000532	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—DHFR—bone cancer	4.03e-05	0.000511	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—NT5C3A—bone cancer	3.94e-05	0.000499	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—NDUFA12—bone cancer	3.89e-05	0.000493	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—ENO2—bone cancer	3.8e-05	0.000482	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—NDUFA12—bone cancer	3.8e-05	0.000481	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—GNA11—bone cancer	3.77e-05	0.000478	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	3.61e-05	0.000458	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—NT5C3A—bone cancer	3.61e-05	0.000458	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—NDUFA12—bone cancer	3.58e-05	0.000454	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—NDUFA12—bone cancer	3.55e-05	0.00045	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—DHFR—bone cancer	3.52e-05	0.000447	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—CYP3A4—bone cancer	3.42e-05	0.000433	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.4e-05	0.000431	CbGpPWpGaD
Lansoprazole—CYP3A4—Biological oxidations—GSTP1—bone cancer	3.34e-05	0.000423	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—GNA11—bone cancer	3.29e-05	0.000418	CbGpPWpGaD
Lansoprazole—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	3.29e-05	0.000417	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—NT5C3A—bone cancer	3.22e-05	0.000409	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—NT5C3A—bone cancer	3.15e-05	0.000399	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—NDUFA12—bone cancer	3.03e-05	0.000384	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—CYP3A4—bone cancer	2.99e-05	0.000379	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—NT5C3A—bone cancer	2.96e-05	0.000376	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—NT5C3A—bone cancer	2.94e-05	0.000373	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—GSTP1—bone cancer	2.92e-05	0.000371	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—ENO2—bone cancer	2.8e-05	0.000355	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	2.68e-05	0.000339	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—DHFR—bone cancer	2.6e-05	0.00033	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	2.58e-05	0.000327	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—GSTP1—bone cancer	2.55e-05	0.000324	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—ENO2—bone cancer	2.55e-05	0.000323	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—NT5C3A—bone cancer	2.51e-05	0.000318	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—GNA11—bone cancer	2.43e-05	0.000308	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—DHFR—bone cancer	2.36e-05	0.0003	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—NDUFA12—bone cancer	2.34e-05	0.000297	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	2.33e-05	0.000295	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—GNA11—bone cancer	2.21e-05	0.00028	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—CYP3A4—bone cancer	2.2e-05	0.000279	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.19e-05	0.000278	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—CYP3A4—bone cancer	2e-05	0.000254	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—NT5C3A—bone cancer	1.94e-05	0.000246	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—GSTP1—bone cancer	1.88e-05	0.000239	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.83e-05	0.000232	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—ENO2—bone cancer	1.72e-05	0.000219	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—GSTP1—bone cancer	1.71e-05	0.000217	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—DHFR—bone cancer	1.6e-05	0.000203	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—ENO2—bone cancer	1.58e-05	0.000201	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.54e-05	0.000195	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PTGS2—bone cancer	1.51e-05	0.000192	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—GNA11—bone cancer	1.5e-05	0.00019	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—DHFR—bone cancer	1.47e-05	0.000186	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—ENO2—bone cancer	1.41e-05	0.000179	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—ENO2—bone cancer	1.38e-05	0.000175	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—GNA11—bone cancer	1.37e-05	0.000174	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—CYP3A4—bone cancer	1.36e-05	0.000172	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.35e-05	0.000171	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PTGS2—bone cancer	1.32e-05	0.000168	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—DHFR—bone cancer	1.31e-05	0.000166	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—ENO2—bone cancer	1.3e-05	0.000165	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—ENO2—bone cancer	1.29e-05	0.000163	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—DHFR—bone cancer	1.28e-05	0.000162	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CYP3A4—bone cancer	1.24e-05	0.000158	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.24e-05	0.000157	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—GNA11—bone cancer	1.22e-05	0.000155	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—DHFR—bone cancer	1.2e-05	0.000153	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—GNA11—bone cancer	1.19e-05	0.000151	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—DHFR—bone cancer	1.19e-05	0.000151	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—GSTP1—bone cancer	1.16e-05	0.000147	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—GNA11—bone cancer	1.13e-05	0.000143	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—GNA11—bone cancer	1.12e-05	0.000142	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CYP3A4—bone cancer	1.11e-05	0.000141	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.1e-05	0.00014	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ENO2—bone cancer	1.1e-05	0.000139	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CYP3A4—bone cancer	1.08e-05	0.000137	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—GSTP1—bone cancer	1.06e-05	0.000135	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CYP3A4—bone cancer	1.02e-05	0.000129	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—DHFR—bone cancer	1.02e-05	0.000129	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CYP3A4—bone cancer	1.01e-05	0.000128	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.01e-05	0.000128	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PTGS2—bone cancer	9.75e-06	0.000124	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—GNA11—bone cancer	9.54e-06	0.000121	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—GSTP1—bone cancer	9.49e-06	0.00012	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—GSTP1—bone cancer	9.26e-06	0.000117	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PTGS2—bone cancer	8.87e-06	0.000113	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—GSTP1—bone cancer	8.73e-06	0.000111	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—GSTP1—bone cancer	8.65e-06	0.00011	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CYP3A4—bone cancer	8.64e-06	0.00011	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	8.6e-06	0.000109	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ENO2—bone cancer	8.49e-06	0.000108	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—DHFR—bone cancer	7.87e-06	9.99e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—GSTP1—bone cancer	7.39e-06	9.38e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GNA11—bone cancer	7.36e-06	9.33e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PTGS2—bone cancer	6.01e-06	7.62e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GSTP1—bone cancer	5.71e-06	7.24e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PTGS2—bone cancer	5.51e-06	6.99e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PTGS2—bone cancer	4.92e-06	6.24e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PTGS2—bone cancer	4.8e-06	6.09e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PTGS2—bone cancer	4.52e-06	5.73e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PTGS2—bone cancer	4.48e-06	5.69e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PTGS2—bone cancer	3.83e-06	4.86e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PTGS2—bone cancer	2.96e-06	3.75e-05	CbGpPWpGaD
